Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronac Mamtani

Showing results (21-30 of 198) with videos related to

Pageof 20
Sort By:
Journal of the National Cancer Institute|April 10, 2015
Thyroid dysfunction, thyroid hormone replacement and colorectal cancer riskBen Boursi, Kevin Haynes, Ronac Mamtani, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2015
Recurrent antibiotic exposure may promote cancer formation--Another step in understanding the role of the human microbiota?Ben Boursi, Ronac Mamtani, Kevin Haynes, et al.
Archives of Dermatological Research|September 11, 2016
An association between newly diagnosed cutaneous T cell lymphoma and prior impetigo: a nested case-control studyBen Boursi, Kevin Haynes, Ronac Mamtani, et al.
Pharmacoepidemiology and Drug Safety|March 27, 2015
Impact of antibiotic exposure on the risk of colorectal cancerBen Boursi, Kevin Haynes, Ronac Mamtani, et al.
European Journal of Endocrinology|March 26, 2015
The effect of past antibiotic exposure on diabetes riskBen Boursi, Ronac Mamtani, Kevin Haynes, et al.
Clinical Lung Cancer|March 19, 2023
Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90Mohsin Shah, Ronac Mamtani, Melina E Marmarelis, et al.
Health Services & Outcomes Research Methodology|June 21, 2021
Bias Reduction Methods for Propensity Scores Estimated from Error-Prone EHR-Derived CovariatesJoanna Harton, Ronac Mamtani, Nandita Mitra, et al.
Clinical Lung Cancer|August 9, 2022
Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung CancerMohsin Shah, Melina E Marmarelis, Ronac Mamtani, et al.
JAMA Oncology|May 13, 2022
Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted TherapyVivek Nimgaonkar, Rebecca A Hubbard, Erica L Carpenter, et al.
Leukemia & Lymphoma|October 6, 2016
Impact of metformin on the progression of MGUS to multiple myelomaBen Boursi, Ronac Mamtani, Yu-Xiao Yang, et al.
Pageof 20

Showing results (21-30 of 198) with videos related to

Sort By:
Pageof 20
Journal of the National Cancer Institute|April 10, 2015
Thyroid dysfunction, thyroid hormone replacement and colorectal cancer riskBen Boursi, Kevin Haynes, Ronac Mamtani, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2015
Recurrent antibiotic exposure may promote cancer formation--Another step in understanding the role of the human microbiota?Ben Boursi, Ronac Mamtani, Kevin Haynes, et al.
Archives of Dermatological Research|September 11, 2016
An association between newly diagnosed cutaneous T cell lymphoma and prior impetigo: a nested case-control studyBen Boursi, Kevin Haynes, Ronac Mamtani, et al.
Pharmacoepidemiology and Drug Safety|March 27, 2015
Impact of antibiotic exposure on the risk of colorectal cancerBen Boursi, Kevin Haynes, Ronac Mamtani, et al.
European Journal of Endocrinology|March 26, 2015
The effect of past antibiotic exposure on diabetes riskBen Boursi, Ronac Mamtani, Kevin Haynes, et al.
Clinical Lung Cancer|March 19, 2023
Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90Mohsin Shah, Ronac Mamtani, Melina E Marmarelis, et al.
Health Services & Outcomes Research Methodology|June 21, 2021
Bias Reduction Methods for Propensity Scores Estimated from Error-Prone EHR-Derived CovariatesJoanna Harton, Ronac Mamtani, Nandita Mitra, et al.
Clinical Lung Cancer|August 9, 2022
Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung CancerMohsin Shah, Melina E Marmarelis, Ronac Mamtani, et al.
JAMA Oncology|May 13, 2022
Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted TherapyVivek Nimgaonkar, Rebecca A Hubbard, Erica L Carpenter, et al.
Leukemia & Lymphoma|October 6, 2016
Impact of metformin on the progression of MGUS to multiple myelomaBen Boursi, Ronac Mamtani, Yu-Xiao Yang, et al.
Pageof 20